Jack Schuler Acquires 82,465 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 82,465 shares of the stock in a transaction on Thursday, January 22nd. The stock was purchased at an average price of $10.96 per share, for a total transaction of $903,816.40. Following the completion of the purchase, the director owned 1,463,210 shares of the company’s stock, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Biodesix Trading Up 9.8%

Shares of BDSX opened at $11.08 on Wednesday. Biodesix, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $21.60. The business has a 50-day moving average of $7.75 and a 200 day moving average of $7.73. The firm has a market cap of $88.15 million, a P/E ratio of -1.99 and a beta of 0.60. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84.

Biodesix (NASDAQ:BDSX) last released its quarterly earnings data on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. As a group, research analysts forecast that Biodesix, Inc. will post -0.35 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and an average price target of $32.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Aberdeen Group plc purchased a new stake in Biodesix during the fourth quarter valued at about $1,784,000. Oracle Investment Management Inc. bought a new position in Biodesix during the 3rd quarter worth approximately $113,000. Millennium Management LLC purchased a new position in Biodesix in the 3rd quarter worth approximately $113,000. Finally, XTX Topco Ltd lifted its position in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after purchasing an additional 102,494 shares during the last quarter. 20.96% of the stock is currently owned by institutional investors.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.